当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2014年
20期
33-34
,共2页
原发性肝癌%出血%肝动脉栓塞化疗术
原髮性肝癌%齣血%肝動脈栓塞化療術
원발성간암%출혈%간동맥전새화료술
Primary hepatocellular carcinoma%Hemorrhage%Transcatheter arterial chemoembolization
目的:研究肝动脉栓塞化疗术治疗原发性肝癌破裂出血患者的临床疗效。方法选取2010年1月~2012年12月保山市人民医院收治的PHCC破裂出血患者10例,右侧股动脉进行穿刺,对肿瘤供血的动脉进行栓塞。对比治疗前后患者的血压、血红蛋白、甲胎蛋白(AFP)及肿瘤大小情况,并对患者进行随访。结果患者术后1周血压、血红蛋白的情况均恢复到正常水平,与治疗前比较,差异有统计学意义(P<0.01);术后2个月患者肿瘤大小及AFP情况明显好转,与治疗前比较,差异有统计学意义(P<0.01)。结论肝动脉栓塞化疗术治疗原发性肝癌破裂出血临床疗效较好,有效改善了患者的预后,但是尚需要大样本、多中心临床试验证实。
目的:研究肝動脈栓塞化療術治療原髮性肝癌破裂齣血患者的臨床療效。方法選取2010年1月~2012年12月保山市人民醫院收治的PHCC破裂齣血患者10例,右側股動脈進行穿刺,對腫瘤供血的動脈進行栓塞。對比治療前後患者的血壓、血紅蛋白、甲胎蛋白(AFP)及腫瘤大小情況,併對患者進行隨訪。結果患者術後1週血壓、血紅蛋白的情況均恢複到正常水平,與治療前比較,差異有統計學意義(P<0.01);術後2箇月患者腫瘤大小及AFP情況明顯好轉,與治療前比較,差異有統計學意義(P<0.01)。結論肝動脈栓塞化療術治療原髮性肝癌破裂齣血臨床療效較好,有效改善瞭患者的預後,但是尚需要大樣本、多中心臨床試驗證實。
목적:연구간동맥전새화료술치료원발성간암파렬출혈환자적림상료효。방법선취2010년1월~2012년12월보산시인민의원수치적PHCC파렬출혈환자10례,우측고동맥진행천자,대종류공혈적동맥진행전새。대비치료전후환자적혈압、혈홍단백、갑태단백(AFP)급종류대소정황,병대환자진행수방。결과환자술후1주혈압、혈홍단백적정황균회복도정상수평,여치료전비교,차이유통계학의의(P<0.01);술후2개월환자종류대소급AFP정황명현호전,여치료전비교,차이유통계학의의(P<0.01)。결론간동맥전새화료술치료원발성간암파렬출혈림상료효교호,유효개선료환자적예후,단시상수요대양본、다중심림상시험증실。
Objective To discuss Effect of transcatheter arterial chemoembolization (TACE) in treatment of primary hepatocellular carcinoma (PHCC) with hemorrhage. Methods 10 cases of the PHCC with hemorrhage were conformed to carry through the right femoral artery puncture, Arterial embolization of tumor blood supply, contrast before and after treatment in patients with blood pressure, hemoglobin, AFP and tumor size, and follow-up the patients. Results After a week ,the patients with blood pressure, hemoglobin, back to normal levels, compared with before treatment were statistically significant (P<0.01);Two months later,the patients with tumor size and AFP cases turn for the better significantly, compared with before treatment,heve statistically significant (P<0.01). Conclusion TACE in treatment of PHCC with hemorrhage has good clinical curative effect, improve the prognosis of patients effectively, but it is need large sample, multi-center clinical trials to confirm.